Dr. Denise Scots-Knight
CEO and Co-Founder
Denise is our CEO, a board member and co-founder of Mereo. Denise has over 25 years experience in the biopharmaceutical industry both in R&D management and as a venture capitalist.
She started her career in R&D management at Amersham and Fisons and as a senior executive at Scientific Generics before joining Rothschild Asset Management as an investment manager. In 1999 she joined Nomura and became Managing Director after heading the life science investment team investing globally in biotechnology companies. She led the Phase4 Partners MBO from Nomura in 2010.
Denise had served on many US and European private and public boards including Idenix (until acquired by Merck for $3.85bn). She is currently a board member of Elanco Animal Health Incorporated. Denise has a PhD and BSc (Hons) from Birmingham University and was a Fulbright scholar at UC Berkeley.
Dr. Peter Fellner
Peter has previously served on the Boards of a wide range of life science companies, including as Chairman of the MedTech company Consort Medical plc until April 2019, Chairman of Vernalis plc until October 2018, Chairman of Ablynx NV from November 2013 until January 2018, Vice-Chairman of Astex Pharmaceuticals Inc. until its sale to Otsuka in 2013, Chairman of Optos plc from 2000 until its acquisition by Nikon Corporation in 2015, Director of the global biopharmaceutical company UCB SA from 2005 to 2014 and Chairman of Acambis plc from 2006 until its acquisition by Sanofi in 2008.
He was Chairman of Celltech Group plc until its acquisition by UCB in 2004, having been CEO from 1990. Before joining Celltech he was CEO of Roche UK from 1986 to 1990. He served as a member of the Medical Research Council from 2000 to 2007.
Richard is our CFO and a board member of Mereo. Richard joins from Shield Therapeutics plc where he has been Chief Financial Officer and Company Secretary. He was initially appointed as a Non-Executive Director at Shield in 2010 before moving to his current position in 2011 where he had a leading role establishing the finance operations and guiding Shield through its recent IPO. Prior to this, Richard had a career in investment banking, holding senior positions at Investec and Brewin Dolphin Securities, where he advised healthcare clients on a wide range of transactions and fundraisings including IPOs, M&A and fundraisings. Richard qualified as a Chartered Accountant with PwC in 1991.
Dr. Anders Ekblom
Anders has extensive experience as an executive and leader with broad business knowledge from senior roles in the biopharmaceutical industry, with global experience delivering products, projects, productivity and change management.
He is currently Chairman/Non-Executive Board member of several biotech companies. During two decades at AstraZeneca, he was a member of global executive teams including Executive VP Global Medicines Development, Global Head Clinical Development, Global Therapy Area Head, Global Head Science & Technology Integration, and CEO AstraZeneca AB Sweden.
Anders is also a board certified MD (Anaesthesiology and Intensive Care), PhD, DDS, and Associate Professor at Karolinska Institute, Stockholm, Sweden and a fellow of the Royal Swedish Academy of Engineering Sciences.
Peter has nearly three decades of experience in the biotech and pharmaceutical industry encompassing strategic and operational leadership expertise across global geographies, functions and business segments.
Previously, he was representative executive officer and chief executive officer of Sosei Group Corporation, a Tokyo listed biotech company, and chief executive officer of Syngene International, which he successfully took public on the Mumbai exchange in 2015.
He also currently serves as non-executive director for Phase4 Partners and MiNA, and is also non-executive chairman of Fermenta Biotech, a subsidiary of DIL, a Mumbai listed company. Previously, he had a 23-year career at GlaxoSmithKline, where he held multiple senior roles. Peter received a BSc Combined (Honours) in Physiology/Zoology from Sheffield University.
Kunal is a Chartered Accountant and is currently Chairman and Managing Director of Allegro Capital Advisors, a leading Indian investment bank. Kunal has a deep understanding of the life sciences industry, built over two decades of advising companies in the industry on fund raising, IPOs, mergers and acquisitions, and IP licensing.
He is an Independent Director of GlaxoSmithKline Consumer Healthcare Ltd and Phase4 Partners. He was also Founder and Executive Director of Celstream Technologies, a leading software product engineering organization. From 1994-2000 he was a global partner at Arthur Andersen responsible for building and developing the firm’s practice in Southern India.
Paul has over 40 years of experience in the field of finance. He has previously held the positions of Senior Vice President Strategic Finance Projects and Financial Controller at GSK gaining extensive emerging markets, corporate finance and change experience.
He also recently served on the GSK Audit and Risk Committee. He is currently a board member of Syngene International and also a member of Syngene’s Audit and Risk Committee and Stakeholder Relationships Committee.
He holds a BSc in Management Sciences from Warwick University and also a professional accounting qualification from the Chartered Institute of Management Accountants.
Dr Deepa Pakianathan
Deepa is a Managing Member at Delphi Ventures and leads all of the firm’s biotechnology investment activities. She joins the Mereo Board subsequent to the merger with OncoMed Pharmaceuticals. She currently serves on the boards of Alder Biopharmaceuticals (Nasdaq:ALDR), Calithera Biosciences (Nasdaq: CALA), and Karyopharm Therapeutics (Nasdaq:KPTI). Deepa joined Delphi in 2001 to build and lead the firm’s biotechnology investment practice. Prior to joining Delphi, Deepa was a Vice President in the healthcare group at J.P. Morgan. Prior to that, she was a biotechnology research analyst at Genesis Merchant Group. She worked as a postdoctoral scientist in the Immunology Department at Genentech Corporation from 1993 to 1997. Deepa received her Ph.D. and MS from Wake Forest University and her MSc and BSc from the University of Bombay.
Learn more about the Board committees: 1) Audit and Risk, 2) Remuneration, 3) Nomination and 4) Research & Development.